ÂÜÀòÂÒÂ×

Dr. Tai-An Lin serves as Senior Vice President of Translational Science and Discovery Biology of Black Diamond Therapeutics. He has more than 25 years of biotechnology and global pharmaceutical experience in advancing multiple drug discovery programs from target identification to early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology.

Prior to joining Black Diamond, Tai-An was a Director of Immuno-Oncology Translational Innovation Platform and Experimental Medicine at Merck KGaA/EMD Serono leading translational biomarker research team and IO precision medicine efforts. Prior to joining EMD Serono, Tai-An had extensive experience in leading multidisciplinary drug discovery teams and biology groups at global pharmaceutical companies including Bristol-Myers Squibb, Roche, and Janssen Pharmaceuticals; key accomplishments included early discovery efforts for several kinase inhibitors including dasatinib, and leadership of BMS’s linrodostat and Roche’s RG7185 projects.

Tai-An earned a Ph.D. in Biochemistry from University of Missouri – Columbia and completed postdoctoral research in Molecular Biology and Pharmacology at Washington University in St Louis, Missouri.